1. Home
  2. INAB vs CCHH Comparison

INAB vs CCHH Comparison

Compare INAB & CCHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.10

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Logo CCH Holdings Ltd Ordinary Shares

CCHH

CCH Holdings Ltd Ordinary Shares

HOLD

Current Price

$1.39

Market Cap

13.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
INAB
CCHH
Founded
2016
2015
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.7M
13.6M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
INAB
CCHH
Price
$1.10
$1.39
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
71.6K
278.4K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$43.55
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.18
52 Week High
$2.73
$15.39

Technical Indicators

Market Signals
Indicator
INAB
CCHH
Relative Strength Index (RSI) 46.50 57.35
Support Level N/A $0.39
Resistance Level $1.50 $1.86
Average True Range (ATR) 0.10 0.15
MACD 0.02 -0.04
Stochastic Oscillator 70.36 27.53

Price Performance

Historical Comparison
INAB
CCHH

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About CCHH CCH Holdings Ltd Ordinary Shares

CCH Holdings Ltd, through its subsidiaries, operates a specialty hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot. The Group offers catering services in Malaysia and outside Malaysia, mainly under two brands, namely Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. It operates or licenses several restaurant outlets, among which include Chicken Claypot House, Zi Wei Yuan, 888 Family Food Courts, and other outlets under the Bibixian, Banbudian Bistro, and Chao Liu Xian Hotpot brands. A large share of its restaurants are located in Malaysia, with additional franchised outlets in Thailand, Indonesia, and China. Geographically, the Group's revenues are all derived from Malaysia.

Share on Social Networks: